retroviral-mediated transfer of iduronate-2-sulfatase gene into lymphocytes

Gene therapyexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 1996 (NCT00004454)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, passive

    immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • retroviral-mediated transfer of iduronate-2-sulfatase gene into lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00004454Phase 1/Phase 2 (Phase 2)Oct 1, 1996National Institutes of Health (NIH), University of Minnesota
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institutes of Health (NIH)Government1111996
University of MinnesotaAcademic/Hospital1011996
2 organizations
Page 1 / 1